Tranylcypromine-Based LSD1 Inhibitors as Useful Agents to Reduce Viability of Schistosoma mansoni.

Schistosoma infections remain a major public health issue mainly in tropical and subtropical regions. While Praziquantel is the primary treatment for schistosomiasis, its limitations include resistance development and poor efficacy against juvenile worms. Given the biological similarities between tumor and parasite-infected cells, LSD1 inhibitors─primarily explored as anticancer agents─have been investigated for their antiparasitic potential.